KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
9/30/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $13,692 | $1,426 | $0 | $0 |
| % Growth | 860.2% | – | – | – |
| Cost of Goods Sold | $1,232 | $590 | $15,891 | $0 |
| Gross Profit | $12,460 | $836 | -$15,891 | $0 |
| % Margin | 91% | 58.6% | – | – |
| R&D Expenses | $11,993 | $15,162 | $15,891 | $12,594 |
| G&A Expenses | $46,517 | $44,683 | $39,139 | $30,346 |
| SG&A Expenses | $46,517 | $44,683 | $39,139 | $30,346 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$15,891 | $0 |
| Operating Expenses | $58,510 | $59,845 | $39,139 | $42,940 |
| Operating Income | -$46,050 | -$59,009 | -$55,030 | -$42,940 |
| % Margin | -336.3% | -4,138.1% | – | – |
| Other Income/Exp. Net | -$1,275 | $1,070 | $1,949 | -$1,322 |
| Pre-Tax Income | -$47,325 | -$57,939 | -$53,081 | -$44,262 |
| Tax Expense | $2,157 | $2,157 | -$855 | $4,247 |
| Net Income | -$49,482 | -$60,096 | -$52,226 | -$48,509 |
| % Margin | -361.4% | -4,214.3% | – | – |
| EPS | -0.92 | -1.12 | -1.05 | -0.92 |
| % Growth | 17.9% | -6.7% | -14.1% | – |
| EPS Diluted | -0.92 | -1.12 | -1.05 | -0.92 |
| Weighted Avg Shares Out | 53,884 | 53,497 | 49,653 | 52,639 |
| Weighted Avg Shares Out Dil | 53,884 | 53,497 | 49,653 | 52,639 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,875 | $1,849 | $1,992 | $1,394 |
| Interest Expense | $4,757 | $3,522 | $2,943 | $2,842 |
| Depreciation & Amortization | $369 | $252 | $261 | $229 |
| EBITDA | -$42,199 | -$54,165 | -$54,769 | -$41,191 |
| % Margin | -308.2% | -3,798.4% | – | – |